Acalabrutinib is named as an intervention in 31 current clinical trials in our USA, UK, China, Ireland and India registers. 13 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is Acerta Pharma BV (15). The most-studied condition is Chronic Lymphocytic Leukemia.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
2 single-substance products containing Acalabrutinib on the HPRA medicines list.
No entry for Acalabrutinib in the EMA, FDA or German BfArM shortage lists we track.
| Condition (as registered) | Trials |
|---|---|
| Chronic Lymphocytic Leukemia | 13 |
| Mantle Cell Lymphoma (MCL) | 4 |
| Small Lymphocytic Lymphoma | 3 |
| Chronic Lymphocytic Leukaemia | 2 |
| Non Hodgkin Lymphoma | 2 |
| Diffuse Large B-Cell Lymphoma | 2 |
| Chronic Lymphocytic Leukemia (CLL) | 1 |
| Small Lymphocytic Lymphoma (SLL) | 1 |
| Mantle-cell Lymphoma | 1 |
| Large B-cell Lymphoma | 1 |
| Waldenström Macroglobulinemia (WM) | 1 |
| Lymphoma, Mantle-Cell | 1 |
| Chronic Lymphocytic Leukemia, CLL | 1 |
| Diffuse Large B Cell Lymphoma | 1 |
| Moderate to Severe Cardiac Impairment | 1 |
| Richter's Syndrome | 1 |
| Prolymphocytic Leukemia | 1 |
| Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | 1 |
| Indolent B-Cell Non-Hodgkin Lymphoma | 1 |
| Lymphoma, Mantle Cell | 1 |
| Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) | 1 |
| Glioblastoma Multiforme | 1 |
| Lead sponsor | Trials |
|---|---|
| Acerta Pharma BV | 15 |
| AstraZeneca | 7 |
| The First Affiliated Hospital with Nanjing Medical University | 2 |
| Loxo Oncology, Inc. | 1 |
| Kartos Therapeutics, Inc. | 1 |
| Merck Sharp & Dohme LLC | 1 |
| BeOne Medicines | 1 |
| AbbVie | 1 |
| BioInvent International AB | 1 |
| Sun Yat-sen University | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 26 | 9 |
| Clinical trials in UK | 18 | 7 |
| Clinical trials in China | 11 | 7 |
| Clinical trials in Ireland | 1 | 1 |
| Clinical trials in India | 1 | 0 |
A trial with sites in more than one country appears in each of those registers.
31 current trials in our USA, UK, China, Ireland and India registers name Acalabrutinib (also registered as ACP-196) as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 13 of the 31 trials are recruiting: 9 with sites in USA, 7 with sites in UK, 7 with sites in China and 1 with sites in Ireland. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Acerta Pharma BV (15), AstraZeneca (7), The First Affiliated Hospital with Nanjing Medical University (2) and Loxo Oncology, Inc (1), among 10 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Yes. The HPRA medicines list includes 2 single-substance products containing Acalabrutinib, for example Calquence 100 mg hard capsules (AstraZeneca AB). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
Not in the lists we track: Acalabrutinib has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Acalabrutinib works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Acalabrutinib works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Acalabrutinib (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.